NCT03798626 2026-04-01
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed
Clinical Trials
71 trialsNCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01130519 2025-02-21
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02724878 2025-02-13
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02020707 2024-07-26
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
Mayo Clinic
Phase 1 Completed
NCT00019539 2024-03-04
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03149003 2023-11-15
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT00942331 2023-10-16
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT02386826 2023-09-21
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
SCRI Development Innovations, LLC
Phase 1 Completed
NCT03063762 2023-02-17
Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Hoffmann-La Roche
Phase 1 Completed
NCT02420821 2023-01-30
IMmotion151
Hoffmann-La Roche
Phase 3 Completed
NCT02348008 2022-09-14
Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:
Big Ten Cancer Research Consortium
Phase 1/2 Completed
NCT01664182 2022-06-07
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00112840 2022-02-01
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01399918 2022-02-01
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02363751 2021-03-09
BEVABEL
UNICANCER
Phase 2 Completed
NCT00113217 2020-09-23
Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT01984242 2019-12-23
IMmotion150
Hoffmann-La Roche
Phase 2 Completed
NCT01083368 2019-08-21
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT00853021 2019-06-05
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01731158 2019-02-06
BERAT
Central European Society for Anticancer Drug Research
Phase 2 Completed
NCT00378703 2018-11-14
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00942578 2018-10-11
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01625936 2018-08-29
CRLX101 Plus Bevacizumab in Advanced RCC
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01727089 2018-08-28
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01656304 2018-07-31
Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT02835833 2018-07-10
Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
University of Alabama at Birmingham
Phase 1 Completed
NCT00499694 2018-06-12
Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT00089609 2018-04-20
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00923130 2018-04-17
Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00782275 2018-01-24
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00992121 2017-11-13
An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma
GlaxoSmithKline
Phase 1 Completed
NCT00496587 2017-07-19
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00658697 2017-05-25
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00574769 2017-04-11
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
University of Southern California
Phase 1/2 Completed
NCT00719264 2017-03-20
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis
Phase 2 Completed
NCT00776594 2016-10-21
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01283048 2016-09-21
Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02627144 2016-08-29
Bevacizumab in Metastatic Renal Cancer
Hoffmann-La Roche
Completed
NCT00072046 2016-07-06
Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00738530 2016-06-23
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Hoffmann-La Roche
Phase 3 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00321646 2016-05-16
Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00631371 2016-04-27
INTORACT
Pfizer
Phase 3 Completed
NCT00506155 2016-03-31
Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00203424 2016-03-25
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
Translational Oncology Research International
Phase 2 Completed
NCT00234494 2016-03-14
Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT00588666 2016-01-22
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00324870 2016-01-13
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed